Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

By afschroeder • December 4, 2025

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan JR, Green MR, Kahl BS, Kridel R, Link BK, Maurer MJ, Nadel B, Radtke A, Luttwak E, Salles GA, Sehn LH, Pasqualucci L, LaCasce AS. Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop. Blood Adv. 2025 Dec 3:bloodadvances.2025018079. doi: 10.1182/bloodadvances.2025018079. Epub ahead of print. PMID: 41337699.

Tags: Hematology/Oncology, Publications

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer

Thaker SK, Silverstein J, Konecny GE, Bardia A. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast[...]

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma

Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber[...]

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]